Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847519 · ClinicalTrials.gov registry record · Phase 1
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Advaxis.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03847519: Completed Phase 1 study, sponsored by Advaxis.
NCT03847519 is a Phase 1 study that has completed, run by Advaxis. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03847519, a Phase 1 study, has completed, sponsored by Advaxis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Interventions
- DRUG Pembrolizumab
- DRUG ADXS-503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03847519
The ClinicalTrials.gov registry entry for NCT03847519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03847519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03847519 about?
NCT03847519 is a clinical study titled "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer". A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
What is the current status of trial NCT03847519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-02-12. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT03847519?
The interventions under investigation include: Pembrolizumab (DRUG), ADXS-503 (DRUG).
Who is sponsoring clinical trial NCT03847519?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.